ʻO ka hoʻomohala ʻana o ka biologics ma waena o nā mea koʻikoʻi e hoʻokūkū nei i ka mākeke lāʻau lapaʻau sinus. Loaʻa ʻo Omalizumab i ka hoihoi o nā mea noiʻi a me nā mea hana lāʻau. Ua loaʻa iā ia ka ʻae ʻia ma ʻEulopa a me ka US e mālama i ka hānō maʻi nui.
I ka poʻe mākua, hiki ke hoʻopili ʻia nā maʻi maʻi sinus me nā ʻano ʻino o ke kino, nā polyps ihu, a me ka mōʻaukala o ka maʻi i ka ʻōpū hanu, nāwaliwali ka palekana.
I nā keiki, hiki ke hana ʻia nā maʻi pili i ka sinus ma muli o ka pacifier, ka ʻike ʻole ʻana i ka uahi lua, ka hānai ʻana i ka wā e moe ai, a pēlā pū. Eia kekahi, ʻo nā maʻi fungal a me nā mea haumia e alakaʻi i ka sinusitis.
Hoʻoiho i ke kope kope o ka hōʻike: https://www.futuremarketinsights.com/reports/sample/rep-gb-12367
Nā Manaʻo Hui Pūʻali
Kuhi ʻia ka mākeke honua e ʻike i ka ulu nui ʻana i ka wā wānana. Ke pāʻani nei nā mea pāʻani mākeke no ka organik a me ke ʻano inorganic o ka hoʻonui.
O kahi laʻana -
- I Iulai 2020, ua hoʻolaha ʻo Tiziana i ka waiho ʻana i ka palapala patent no ka hoʻokele ihu o Foralumab. ʻO Foralumab kahi 100% kanaka Anti-CD3 monoclonal antibody e mālama i nā maʻi maʻi Covid-19.
- I Iune 2019, ua hoʻolaha ʻo Sanofi a me Regeneron Pharmaceuticals, Inc. i ka ʻae ʻana iā Dupixent (dupilumab) e ka US FDA e hoʻohana pū me nā lāʻau ʻē aʻe no ka mālama ʻana i ka CRSwNP (chronic rhinosinusitis me ka polyposis nasal).
Ke ki kuai âlapa pôhili me uhiʻia e FMI nā Bausch Health, Nоvаrtіѕ АG, Ѕun Рhаrmасеutісаl Іnduѕtrіеѕ, Іnс., Rеddу'ѕ Lаbоrаtоrіеѕ, Іnс., Теа Рhаrmасеutісаl Іnduѕtrіеѕ Ltd., Frеѕеnіuѕ Каbі UЅА, Јоhnѕоn & Јоhnѕоn, Рfіzеr Іnс., Јаnѕѕеn Рhаrmасеutісаlѕ, Іnс., a me GlaxoSmithKline plc.
E noi i kahi TOC piha o kēia hōʻike me nā helu: https://www.futuremarketinsights.com/toc/rep-gb-12367
Ke Kumu Loaʻa
- Ua mālama ʻia nā ʻōpala nasal steroid i ka māhele mākeke nui loa ma 2019 a ke manaʻo ʻia nei ke ʻano e hoʻomau ʻia i ka wā e hiki mai ana.
- Ua helu ʻo ʻAmelika ʻĀkau ma mua o 30% o ka māhele mākeke ma 2019
- Noho mau nā lāʻau antibiotic i ka lālani pale mua, a e ulu mau ana kēia ʻāpana i ka wikiwiki a hiki i 2030
- Ua hoʻohuli ʻo Covid-19 i ka noiʻi e pili ana i ka hāʻawi ʻana i ka lāʻau lapaʻau ihu, ka mea e pōmaikaʻi ai i ka mākeke lāʻau lapaʻau sinus.
Makemake ʻoe i nā ʻike hou aʻe?
Lawe ʻo Future Market Insights i ka hōʻike noiʻi piha e pili ana i ka ulu ʻana o ka loaʻa kālā ma ka pae honua, kūloko, a me ka ʻāina a hāʻawi i kahi loiloi o nā ʻano ʻoihana hou loa i kēlā me kēia o nā ʻāpana mai 2015 a 2030. kikoʻī e uhi i kēlā me kēia ʻāpana o ka mākeke a hōʻike i kahi ʻano ʻike mākaʻikaʻi piha i ka mea heluhelu.
Hāʻawi ka haʻawina i nā ʻike koʻikoʻi e pili ana i ka mākeke lāʻau lapaʻau sinus ma ke kumu o ka papa lāʻau (Аntіhіѕtаmіnеѕ, Аnаlgеѕісѕ, Ѕulрhоnаmіdеѕ, Соrtісоѕtеrоidѕ, Аntіbіоtаmіnеѕ, Аntіbіоtаmіnеѕ, Аnаlgеѕісѕ, Ѕulрhоnаmіdеѕ, Соrtісоѕtеrоіdѕ, Аntіbіоtаmіnеѕ, Аntіbіоtаmісеѕ Sinurіѕ, NSAcute Sinusitis Sinusitis, NSAcute Sinusitis, NSA, NSA, NSA, Аntіbіоtаmісе, NSA, NSA, NSA, NSA, NSA, NSA. , ke ala o ka hooponopono ana (Oral, Topical, Injectable), a me ke alahele hoolaha (hale ma'i lapaau, hale kuai, laau lapaau online) ma na wahi nui ehiku.
Māhele kī
Ke ala o ka hoʻokele
Kaha Haina
- Nā lāʻau lapaʻau lāʻau
- Nā Hale kūʻai lāʻau kūʻai
- Nā hale kūʻai lāʻau lapaʻau pūnaewele
ʻAno maʻi
- Sinusitis Acute
- Sinusitis Sub-acute
- Sinusitis mau
ʻO Geography
- North America
- Lakina Amerika
- ʻEulopa
- ʻO Asia Hikina
- ʻO Kona Hema
- Oceania
- Waena Hikina a me ʻApika
About Ka Makahiki Hou (FMI)
ʻO ka Future Market Insights (ESOMAR i hōʻoia ʻia i ka ʻoihana noiʻi mākeke a me kahi lālā o Greater New York Chamber of Commerce) hāʻawi i nā ʻike hohonu i nā kumu hoʻokele e hoʻokiʻekiʻe ana i ka noi ma ka mākeke. Hōʻike ia i nā manawa kūpono e makemake ai i ka ulu ʻana o ka mākeke ma nā ʻāpana like ʻole ma ke kumu o Source, Application, Sales Channel a me ka hoʻohana hope ʻana i nā makahiki 10 e hiki mai ana.
Kāhea iā mā˚ou:
Nā Hōʻikeʻike o ka Makahiki Hou
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A
ʻO Jumeirah Lakes Towers, Dubai
Aupuni ʻEmira ʻAlapia Hui Pū ʻia